Adial Pharmaceuticals (ADIL) Accumulated Expenses (2018 - 2026)
Adial Pharmaceuticals (ADIL) posted Accumulated Expenses of $40000.0 for Q1 2026, down 93.94% sequentially from $660307.0 in Q4 2025, and down 94.73% YoY from $758695.0 in Q1 2025.
Adial Pharmaceuticals (ADIL) Accumulated Expenses (2018 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Accumulated Expenses for 9 years, with the latest figure at $40000.0 in Q1 2026.
- Quarterly Accumulated Expenses fell 94.73% year-over-year to $40000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40000.0 (down 94.73% YoY) and the FY2025 annual result came in at $660307.0, down 2.53% from the prior year.
- Accumulated Expenses eased to $40000.0 in Q1 2026 per ADIL's latest filing, from $660307.0 in the prior quarter.
- Over five years, Accumulated Expenses peaked at $963327.0 in Q4 2022 and troughed at $30000.0 in Q3 2023.
- A 5-year average of $436766.4 and a median of $413557.0 in 2024 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2023 and 2024: Accumulated Expenses plunged 95.63% in 2023, then jumped 1278.52% in 2024.
- Over 5 years, Accumulated Expenses stood at $963327.0 in 2022, then plunged by 50.41% to $477747.0 in 2023, then surged by 41.8% to $677456.0 in 2024, then dropped by 2.53% to $660307.0 in 2025, then tumbled by 93.94% to $40000.0 in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $40000.0, $660307.0, and $513169.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40,000.00 |
| Dec 31, 2025 | 660,307.00 |
| Sep 30, 2025 | 513,169.00 |
| Jun 30, 2025 | 372,560.00 |
| Mar 31, 2025 | 758,695.00 |
| Dec 31, 2024 | 677,456.00 |
| Sep 30, 2024 | 413,557.00 |
| Jun 30, 2024 | 273,578.00 |
| Mar 31, 2024 | 375,263.00 |
| Dec 31, 2023 | 477,747.00 |
| Sep 30, 2023 | 30,000.00 |
| Jun 30, 2023 | 276,705.00 |
| Mar 31, 2023 | 50,000.00 |
| Dec 31, 2022 | 963,327.00 |
| Sep 30, 2022 | 686,501.00 |
| Jun 30, 2022 | 498,628.00 |
| Mar 31, 2022 | 357,535.00 |
| Dec 31, 2021 | 520,795.00 |
| Sep 30, 2021 | 444,564.00 |
| Jun 30, 2021 | 278,951.00 |